Watch our webinar with Neurizon Therapeutics, featuring Interim Executive Chairman Sergio Duchini and CFO Dan O'Connell. A presentation followed by live Q&A with the audience.


Neurizon Therapeutics (ASX: NUZ; OTCQB: NUZTF) is a clinical-stage biotechnology company developing NUZ-001 for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease.
NUZ-001 is currently being evaluated in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial in the United States, which has completed recruitment of 250 participants and is progressing toward topline results anticipated in late Q2 CY2027. Neurizon has also recently established an NIH-funded Expanded Access Program through the Healey & AMG Center, broadening patient access to NUZ-001 and further strengthening the clinical infrastructure around the program.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.